Brokerages expect Inovalon Holdings Inc (NASDAQ:INOV) to announce $118.28 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Inovalon’s earnings, with the highest sales estimate coming in at $119.20 million and the lowest estimate coming in at $116.70 million. Inovalon posted sales of $96.09 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.1%. The firm is expected to announce its next earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that Inovalon will report full year sales of $118.28 million for the current financial year, with estimates ranging from $450.00 million to $453.90 million. For the next year, analysts expect that the company will post sales of $492.63 million per share, with estimates ranging from $477.50 million to $505.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Inovalon.

Inovalon (NASDAQ:INOV) last announced its quarterly earnings results on Wednesday, November 1st. The technology company reported $0.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.01. Inovalon had a return on equity of 4.63% and a net margin of 4.07%. The business had revenue of $115.90 million for the quarter, compared to analyst estimates of $114.79 million. During the same quarter in the prior year, the company posted $0.10 EPS. The company’s quarterly revenue was up 10.4% on a year-over-year basis.

INOV has been the topic of several research reports. Zacks Investment Research lowered Inovalon from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. ValuEngine raised Inovalon from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. BidaskClub lowered Inovalon from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. KeyCorp reissued a “hold” rating on shares of Inovalon in a research note on Tuesday, September 12th. Finally, Morgan Stanley raised Inovalon from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $9.00 to $14.00 in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company. Inovalon presently has an average rating of “Hold” and a consensus price target of $12.00.

Inovalon (NASDAQ INOV) traded up $0.05 on Thursday, reaching $14.50. The company had a trading volume of 502,400 shares, compared to its average volume of 541,350. Inovalon has a 1 year low of $10.25 and a 1 year high of $17.80. The company has a current ratio of 5.62, a quick ratio of 5.62 and a debt-to-equity ratio of 0.31. The firm has a market cap of $2,170.00 and a price-to-earnings ratio of 120.83.

In other news, insider Shauna L. Vernal sold 5,908 shares of the stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $16.01, for a total value of $94,587.08. Following the transaction, the insider now owns 47,309 shares in the company, valued at approximately $757,417.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Robert A. Wychulis sold 85,828 shares of the stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $15.54, for a total value of $1,333,767.12. Following the completion of the transaction, the president now owns 466,286 shares in the company, valued at approximately $7,246,084.44. The disclosure for this sale can be found here. 48.28% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in INOV. Dimensional Fund Advisors LP purchased a new position in shares of Inovalon in the 1st quarter valued at about $650,000. Bank of Montreal Can boosted its position in shares of Inovalon by 0.4% in the 2nd quarter. Bank of Montreal Can now owns 14,006 shares of the technology company’s stock valued at $184,000 after purchasing an additional 61 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Inovalon by 93.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 290,293 shares of the technology company’s stock valued at $3,818,000 after purchasing an additional 140,566 shares during the period. Rhumbline Advisers boosted its position in shares of Inovalon by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 68,592 shares of the technology company’s stock valued at $902,000 after purchasing an additional 6,673 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Inovalon by 9.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 344,848 shares of the technology company’s stock valued at $4,535,000 after purchasing an additional 30,922 shares during the period. Institutional investors and hedge funds own 28.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/04/118-28-million-in-sales-expected-for-inovalon-holdings-inc-inov-this-quarter-2.html.

Inovalon Company Profile

Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.

Get a free copy of the Zacks research report on Inovalon (INOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.